{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:46:36Z","timestamp":1790005596794,"version":"4.0.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,3,20]],"date-time":"2018-03-20T00:00:00Z","timestamp":1521504000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"AbbVie Spain"},{"name":"Foundation Neurociencias y Envejecimiento"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s00415-018-8803-1","type":"journal-article","created":{"date-parts":[[2018,3,20]],"date-time":"2018-03-20T07:18:36Z","timestamp":1521530316000},"page":"1279-1287","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Improvement of impulse control disorders associated with levodopa\u2013carbidopa intestinal gel treatment in advanced Parkinson\u2019s disease"],"prefix":"10.1007","volume":"265","author":[{"name":"On behalf of the EDIS Study Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jose","family":"Catalan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Antonio","family":"Molina-Arjona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Mir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Cubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Matias","family":"Arbelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Martinez-Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,20]]},"reference":[{"key":"8803_CR1","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1097\/00005072-199603000-00001","volume":"55","author":"LS Forno","year":"1996","unstructured":"Forno LS (1996) Neuropathology of Parkinson\u2019s disease. J Neuropathol Exp Neurol 55:259\u2013272","journal-title":"J Neuropathol Exp Neurol"},{"key":"8803_CR2","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1046\/j.1440-1789.2001.00403.x","volume":"21","author":"H Takahashi","year":"2001","unstructured":"Takahashi H, Wakabayashi K (2001) The cellular pathology of Parkinson\u2019s disease. Neuropathology 21:315\u2013322","journal-title":"Neuropathology"},{"key":"8803_CR3","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/S1471-1931(00)00031-8","volume":"23","author":"JA Obeso","year":"2000","unstructured":"Obeso JA, Olanow CW, Nutt JG (2000) Levodopa motor complications in Parkinson\u2019s disease. Trends Neurosci 23:S2\u2013S7","journal-title":"Trends Neurosci"},{"key":"8803_CR4","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1212\/WNL.63.8_suppl_3.S35","volume":"63","author":"P Barone","year":"2004","unstructured":"Barone P, Amboni M, Vitale C, Bonavita V (2004) Treatment of nocturnal disturbances and excessive daytime sleepiness in Parkinson\u2019s disease. Neurology 63:S35\u2013S38","journal-title":"Neurology"},{"key":"8803_CR5","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1001\/archneurol.2010.65","volume":"67","author":"D Weintraub","year":"2010","unstructured":"Weintraub D, Koester J, Potenza MN et al (2010) Impulse control disorders in parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 67:589\u2013595. \n                    https:\/\/doi.org\/10.1001\/archneurol.2010.65","journal-title":"Arch Neurol"},{"key":"8803_CR6","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1002\/mds.22571","volume":"24","author":"D Weintraub","year":"2009","unstructured":"Weintraub D, Hoops S, Shea JA, Lyons KE, Pahwa R, Driver-Dunckley ED, Adler CH, Potenza MN, Miyasaki J, Siderowf AD, Duda JE, Hurtig HI, Colcher A, Horn SS, Stern MB, Voon V (2009) Validation of the questionnaire for impulsive-compulsive disorders in Parkinson\u2019s disease. Mov Disord 24:1461\u20131467. \n                    https:\/\/doi.org\/10.1002\/mds.22571","journal-title":"Mov Disord"},{"key":"8803_CR7","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1586\/14737175.6.10.1403","volume":"6","author":"D Nyholm","year":"2006","unstructured":"Nyholm D (2006) Enteral levodopa\/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson\u2019s disease. Expert Rev Neurother 6:1403\u20131411. \n                    https:\/\/doi.org\/10.1586\/14737175.6.10.1403","journal-title":"Expert Rev Neurother"},{"key":"8803_CR8","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1002\/mds.22596","volume":"24","author":"H Honig","year":"2009","unstructured":"Honig H, Antonini A, Martinez-Martin P, Forgacs I, Faye GC, Fox T, Fox K, Mancini F, Canesi M, Odin P, Chaudhuri KR (2009) Intrajejunal levodopa infusion in Parkinson\u2019s disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord 24:1468\u20131474. \n                    https:\/\/doi.org\/10.1002\/mds.22596","journal-title":"Mov Disord"},{"key":"8803_CR9","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.parkreldis.2009.07.015","volume":"16","author":"V Puente","year":"2010","unstructured":"Puente V, De Fabregues O, Oliveras C, Ribera G, Pont-Sunyer C, Vivanco R, Cucurella G, Giralt E, Delgado T, Garcia C, Seoane A, Campo R (2010) Eighteen month study of continuous intraduodenal levodopa infusion in patients with advanced Parkinson\u2019s disease: impact on control of fluctuations and quality of life. Parkinsonism Relat Disord 16:218\u2013221. \n                    https:\/\/doi.org\/10.1016\/j.parkreldis.2009.07.015","journal-title":"Parkinsonism Relat Disord"},{"key":"8803_CR10","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","volume":"55","author":"AJ Hughes","year":"1992","unstructured":"Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson\u2019s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181\u2013184","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"8803_CR11","first-page":"767","volume":"112","author":"A Lobo","year":"1999","unstructured":"Lobo A, Saz P, Marcos G, Dia JL, de la Camara C, Ventura T, Morales Asin F, Fernando Pascual L, Montanes JA, Aznar S (1999) Revalidation and standardization of the cognition mini-exam (first Spanish version of the Mini-Mental Status Examination) in the general geriatric population. Med Clin 112:767\u2013774","journal-title":"Med Clin"},{"key":"8803_CR12","first-page":"153","volume-title":"Recent development in Parkinson\u2019s disease Macmillan Healthcare","author":"S Fahn","year":"1987","unstructured":"Fahn S, Elton R (1987) Unified Parkinson\u2019s disease rating scale. In: Fahn S, Marsden C, Calne D, Goldstein M (eds) Recent development in Parkinson\u2019s disease Macmillan Healthcare. Florham Park, NJ, pp 153\u2013163"},{"key":"8803_CR13","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/mds.22320","volume":"24","author":"P Martinez-Martin","year":"2009","unstructured":"Martinez-Martin P, Rodriguez-Blazquez C, Forjaz MJ, de Pedro J (2009) The clinical impression of severity Index for Parkinson\u2019s Disease: international validation study. Mov Disord 24:211\u2013217. \n                    https:\/\/doi.org\/10.1002\/mds.22320","journal-title":"Mov Disord"},{"key":"8803_CR14","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1007\/s00415-012-6490-x","volume":"259","author":"P Martinez-Martin","year":"2012","unstructured":"Martinez-Martin P, Frades-Payo B, Aguera-Ortiz L, Ayuga-Martinez A (2012) A short scale for evaluation of neuropsychiatric disorders in Parkinson\u2019s disease: first psychometric approach. J Neurol 259:2299\u20132308. \n                    https:\/\/doi.org\/10.1007\/s00415-012-6490-x","journal-title":"J Neurol"},{"key":"8803_CR15","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1176\/jnp.12.2.233","volume":"12","author":"DI Kaufer","year":"2000","unstructured":"Kaufer DI, Cummings JL, Ketchel P, Smith V, MacMillan A, Shelley T, Lopez OL, DeKosky ST (2000) Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatr Clin Neurosci 12:233\u2013239","journal-title":"J Neuropsychiatr Clin Neurosci"},{"key":"8803_CR16","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1002\/mds.21844","volume":"22","author":"B Dubois","year":"2007","unstructured":"Dubois B, Burn D, Goetz C, Aarsland D, Brown RG, Broe GA, Dickson D, Duyckaerts C, Cummings J, Gauthier S, Korczyn A, Lees A, Levy R, Litvan I, Mizuno Y, McKeith IG, Olanow CW, Poewe W, Sampaio C, Tolosa E, Emre M (2007) Diagnostic procedures for Parkinson\u2019s disease dementia: recommendations from the movement disorder society task force. Mov Disord 22:2314\u20132324. \n                    https:\/\/doi.org\/10.1002\/mds.21844","journal-title":"Mov Disord"},{"key":"8803_CR17","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1002\/mds.22110","volume":"23","author":"P Martinez-Martin","year":"2008","unstructured":"Martinez-Martin P, Visser M, Rodriguez-Blazquez C, Marinus J, Chaudhuri KR, van Hilten JJ (2008) SCOPA-sleep and PDSS: two scales for assessment of sleep disorder in Parkinson\u2019s disease. Mov Disord 23:1681\u20131688. \n                    https:\/\/doi.org\/10.1002\/mds.22110","journal-title":"Mov Disord"},{"key":"8803_CR18","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0895-4356(02)00569-3","volume":"56","author":"J Marinus","year":"2003","unstructured":"Marinus J, Visser M, Mart\u0131\u0301nez-Mart\u0131\u0301n P, van Hilten JJ, Stiggelbout AM (2003) A short psychosocial questionnaire for patients with Parkinson\u2019s disease: the SCOPA-PS. J Clin Epidemiol 56:61\u201367. \n                    https:\/\/doi.org\/10.1016\/S0895-4356(02)00569-3","journal-title":"J Clin Epidemiol"},{"key":"8803_CR19","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1002\/mds.21355","volume":"22","author":"P Martinez-Martin","year":"2007","unstructured":"Martinez-Martin P, Forjaz MJ, Frades-Payo B, Rusinol AB, Fernandez-Garcia JM, Benito-Leon J, Arillo VC, Barbera MA, Sordo MP, Catalan MJ (2007) Caregiver burden in Parkinson\u2019s disease. Mov Disord 22:924\u2013931. \n                    https:\/\/doi.org\/10.1002\/mds.21355","journal-title":"Mov Disord"},{"key":"8803_CR20","doi-asserted-by":"publisher","first-page":"S178","DOI":"10.1097\/00005650-198903001-00015","volume":"27","author":"LE Kazis","year":"1989","unstructured":"Kazis LE, Anderson JJ, Meenan RF (1989) Effect sizes for interpreting changes in health status. Med Care 27:S178\u2013S189","journal-title":"Med Care"},{"key":"8803_CR21","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1097\/01.mlr.0000062554.74615.4c","volume":"41","author":"GR Norman","year":"2003","unstructured":"Norman GR, Sloan JA, Wyrwich KW (2003) Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 41:582\u2013592. \n                    https:\/\/doi.org\/10.1097\/01.mlr.0000062554.74615.4c","journal-title":"Med Care"},{"key":"8803_CR22","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1002\/ana.22356","volume":"69","author":"V Voon","year":"2011","unstructured":"Voon V, Sohr M, Lang AE, Potenza MN, Siderowf AD, Whetteckey J, Weintraub D, Wunderlich GR, Stacy M (2011) Impulse control disorders in Parkinson disease: a multicenter case-control study. Ann Neurol 69:986\u2013996. \n                    https:\/\/doi.org\/10.1002\/ana.22356","journal-title":"Ann Neurol"},{"key":"8803_CR23","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jocn.2013.02.032","volume":"21","author":"AL Phu","year":"2014","unstructured":"Phu AL, Xu Z, Brakoulias V, Mahant N, Fung VS, Moore GD, Martin A, Starcevic V, Krause M (2014) Effect of impulse control disorders on disability and quality of life in Parkinson\u2019s disease patients. J Clin Neurosci 21:63\u201366. \n                    https:\/\/doi.org\/10.1016\/j.jocn.2013.02.032","journal-title":"J Clin Neurosci"},{"key":"8803_CR24","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1002\/gps.2704","volume":"27","author":"I Leroi","year":"2012","unstructured":"Leroi I, Harbishettar V, Andrews M, McDonald K, Byrne EJ, Burns A (2012) Carer burden in apathy and impulse control disorders in Parkinson\u2019s disease. Int J Geriatr Psychiatry 27:160\u2013166. \n                    https:\/\/doi.org\/10.1002\/gps.2704","journal-title":"Int J Geriatr Psychiatry"},{"key":"8803_CR25","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3233\/jpd-120165","volume":"3","author":"MB Callesen","year":"2013","unstructured":"Callesen MB, Scheel-Kruger J, Kringelbach ML, Moller A (2013) A systematic review of impulse control disorders in Parkinson\u2019s disease. J Parkinsons Dis 3:105\u2013138. \n                    https:\/\/doi.org\/10.3233\/jpd-120165","journal-title":"J Parkinsons Dis"},{"key":"8803_CR26","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.parkreldis.2016.06.005","volume":"30","author":"S Krishnamoorthy","year":"2016","unstructured":"Krishnamoorthy S, Rajan R, Banerjee M, Kumar H, Sarma G, Krishnan S, Sarma S, Kishore A (2016) Dopamine D3 receptor Ser9Gly variant is associated with impulse control disorders in Parkinson\u2019s disease patients. Parkinsonism Relat Disord 30:13\u201317. \n                    https:\/\/doi.org\/10.1016\/j.parkreldis.2016.06.005","journal-title":"Parkinsonism Relat Disord"},{"key":"8803_CR27","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1136\/jnnp-2013-306787","volume":"85","author":"PJ Garcia-Ruiz","year":"2014","unstructured":"Garcia-Ruiz PJ, Martinez Castrillo JC, Alonso-Canovas A, Herranz Barcenas A, Vela L, Sanchez Alonso P, Mata M, Olmedilla Gonzalez N, Mahillo Fernandez I (2014) Impulse control disorder in patients with Parkinson\u2019s disease under dopamine agonist therapy: a multicentre study. J Neurol Neurosurg Psychiatry 85:840\u2013844. \n                    https:\/\/doi.org\/10.1136\/jnnp-2013-306787","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"8803_CR28","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1111\/ene.12646","volume":"22","author":"H Baumann-Vogel","year":"2015","unstructured":"Baumann-Vogel H, Valko PO, Eisele G, Baumann CR (2015) Impulse control disorders in Parkinson\u2019s disease: don\u2019t set your mind at rest by self-assessments. Eur J Neurol 22:603\u2013609. \n                    https:\/\/doi.org\/10.1111\/ene.12646","journal-title":"Eur J Neurol"},{"key":"8803_CR29","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s00415-016-8079-2","volume":"263","author":"L Ricciardi","year":"2016","unstructured":"Ricciardi L, Demartini B, Pomponi M, Ricciardi D, Morabito B, Renna R, Bernabei R, Bentivoglio AR (2016) Impulsive compulsive behaviours in Parkinson\u2019s disease: patients\u2019 versus caregivers\u2019 perceptions. J Neurol 263:1019\u20131021. \n                    https:\/\/doi.org\/10.1007\/s00415-016-8079-2","journal-title":"J Neurol"},{"key":"8803_CR30","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1007\/s00415-012-6798-6","volume":"260","author":"J Volkmann","year":"2013","unstructured":"Volkmann J, Albanese A, Antonini A, Chaudhuri KR, Clarke CE, de Bie RMA, Deuschl G, Eggert K, Houeto J-L, Kulisevsky J, Nyholm D, Odin P, \u00d8stergaard K, Poewe W, Pollak P, Rabey JM, Rascol O, Ruzicka E, Samuel M, Speelman H, Sydow O, Valldeoriola F, van der Linden C, Oertel W (2013) Selecting deep brain stimulation or infusion therapies in advanced Parkinson\u2019s disease: an evidence-based review. J Neurol 260:2701\u20132714. \n                    https:\/\/doi.org\/10.1007\/s00415-012-6798-6","journal-title":"J Neurol"},{"key":"8803_CR31","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/00002826-200203000-00006","volume":"25","author":"D Nyholm","year":"2002","unstructured":"Nyholm D, Lennernas H, Gomes-Trolin C, Aquilonius SM (2002) Levodopa pharmacokinetics and motor performance during activities of daily living in patients with Parkinson\u2019s disease on individual drug combinations. Clin Neuropharmacol 25:89\u201396","journal-title":"Clin Neuropharmacol"},{"key":"8803_CR32","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1002\/ana.20822","volume":"59","author":"AH Evans","year":"2006","unstructured":"Evans AH, Pavese N, Lawrence AD, Tai YF, Appel S, Doder M, Brooks DJ, Lees AJ, Piccini P (2006) Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neurol 59:852\u2013858. \n                    https:\/\/doi.org\/10.1002\/ana.20822","journal-title":"Ann Neurol"},{"key":"8803_CR33","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1097\/WNF.0000000000000091","volume":"38","author":"A Todorova","year":"2015","unstructured":"Todorova A, Samuel M, Brown RG, Chaudhuri KR (2015) Infusion therapies and development of impulse control disorders in advanced parkinson disease: clinical experience after 3 years\u2019 Follow-up. Clin Neuropharmacol 38:132\u2013134. \n                    https:\/\/doi.org\/10.1097\/wnf.0000000000000091","journal-title":"Clin Neuropharmacol"},{"key":"8803_CR34","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1002\/mds.25636","volume":"28","author":"MJ Catalan","year":"2013","unstructured":"Catalan MJ, de Pablo-Fernandez E, Villanueva C, Fernandez-Diez S, Lapena-Montero T, Garcia-Ramos R, Lopez-Valdes E (2013) Levodopa infusion improves impulsivity and dopamine dysregulation syndrome in Parkinson\u2019s disease. Mov Disord 28:2007\u20132010. \n                    https:\/\/doi.org\/10.1002\/mds.25636","journal-title":"Mov Disord"},{"key":"8803_CR35","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jocn.2015.05.059","volume":"25","author":"FC Chang","year":"2016","unstructured":"Chang FC, Kwan V, van der Poorten D, Mahant N, Wolfe N, Ha AD, Griffith JM, Tsui D, Kim SD, Fung VS (2016) Intraduodenal levodopa-carbidopa intestinal gel infusion improves both motor performance and quality of life in advanced Parkinson\u2019s disease. J Clin Neurosci 25:41\u201345. \n                    https:\/\/doi.org\/10.1016\/j.jocn.2015.05.059","journal-title":"J Clin Neurosci"},{"key":"8803_CR36","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S1474-4422(06)70411-2","volume":"5","author":"A Schrag","year":"2006","unstructured":"Schrag A, Schott JM (2006) Epidemiological, clinical, and genetic characteristics of early onset parkinsonism. Lancet Neurol 5:355\u2013363. \n                    https:\/\/doi.org\/10.1016\/s1474-4422(06)70411-2","journal-title":"Lancet Neurol"},{"key":"8803_CR37","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1007\/s00415-011-6098-6","volume":"258","author":"E Havlikova","year":"2011","unstructured":"Havlikova E, van Dijk JP, Nagyova I, Rosenberger J, Middel B, Dubayova T, Gdovinova Z, Groothoff JW (2011) The impact of sleep and mood disorders on quality of life in Parkinson\u2019s disease patients. J Neurol 258:2222\u20132229. \n                    https:\/\/doi.org\/10.1007\/s00415-011-6098-6","journal-title":"J Neurol"},{"key":"8803_CR38","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1007\/s00415-009-5141-3","volume":"256","author":"S Perez-Lloret","year":"2009","unstructured":"Perez-Lloret S, Rossi M, Nouzeilles MI, Trenkwalder C, Cardinali DP, Merello M (2009) Parkinson\u2019s disease sleep scale, sleep logs, and actigraphy in the evaluation of sleep in parkinsonian patients. J Neurol 256:1480\u20131484. \n                    https:\/\/doi.org\/10.1007\/s00415-009-5141-3","journal-title":"J Neurol"},{"key":"8803_CR39","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.parkreldis.2015.03.024","volume":"21","author":"P Martinez-Martin","year":"2015","unstructured":"Martinez-Martin P, Rodriguez-Blazquez C, Forjaz MJ, Frades-Payo B, Ag\u00fcera-Ortiz L, Weintraub D, Riesco A, Kurtis MM, Chaudhuri KR (2015) Neuropsychiatric symptoms and caregiver\u2019s burden in Parkinson\u2019s disease. Parkinsonism Relat Disord 21:629\u2013634. \n                    https:\/\/doi.org\/10.1016\/j.parkreldis.2015.03.024","journal-title":"Parkinsonism Relat Disord"},{"key":"8803_CR40","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1212\/WNL.0b013e3182840678","volume":"80","author":"D Okai","year":"2013","unstructured":"Okai D, Askey-Jones S, Samuel M, O\u2019Sullivan SS, Chaudhuri KR, Martin A, Mack J, Brown RG, David AS (2013) Trial of CBT for impulse control behaviors affecting Parkinson patients and their caregivers. Neurology 80:792\u2013799. \n                    https:\/\/doi.org\/10.1212\/WNL.0b013e3182840678","journal-title":"Neurology"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-018-8803-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-018-8803-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-018-8803-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,19]],"date-time":"2019-03-19T20:20:44Z","timestamp":1553026844000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-018-8803-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,20]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["8803"],"URL":"https:\/\/doi.org\/10.1007\/s00415-018-8803-1","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,20]]},"assertion":[{"value":"25 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The study complies with the Declaration of Helsinki. Local ethics committees approved the EDIS study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}},{"value":"Maria Jose Catalan has received honoraria for consulting, advisory services, speaking services and research from AbbVie Laboratories and Merz. Antonio Molina-Arjona declares he has no conflict of interest. Pablo Mir has received honoraria for lecturing or advisory boards from AbbVie, UCB, Allergan, and Merz, and research grants from the Ministerio de Econom\u00eda y Competitividad de Espa\u00f1a [SAF2007-60700], Instituto de Salud Carlos III [PI10\/01674, CP08\/00174, PI13\/01461], Consejer\u00eda de Econom\u00eda, Innovaci\u00f3n, Ciencia y Empleo de la Junta de Andaluc\u00eda [CVI-02526, CTS-7685], Consejer\u00eda de Salud y Bienestar Social de la Junta de Andaluc\u00eda [PI-0377\/2007, PI-0741\/2010, PI-0437-2012], Sociedad Andaluza de Neurolog\u00eda, the Jacques and Gloria Gossweiler Foundation, and the Fundaci\u00f3n Alicia Koplowitz. Esther Cubo has received travel grant to meetings from Abbvie and Allergan; speaker honorarium from Abbvie and UCB. Jose Matias Arbelo has received honoraria for educational presentations or clinical studies participation by Abbvie, UCB Pharma and Italfarmaco. Pablo Martinez-Martin has received honorarium from Editorial Viguera and Movement Disorder Society for lecturing in courses; from AbbVie for speaking in experts\u2019 meetings and for participating in the Advisory Board of an epidemiological study. Grant: from the International Parkinson and Movement Disorder Society for the Pilot Study of the MDS-Non-Motor Symptoms Scale.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All patients and caregivers provided written informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}